Pharmacoeconomics

Papers
(The H4-Index of Pharmacoeconomics is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-09-01 to 2024-09-01.)
ArticleCitations
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)401
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment133
Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018124
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis71
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study63
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers58
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment49
EQ-5D-Y Value Set for Slovenia47
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations45
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study43
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia38
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures38
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice36
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review34
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review34
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension32
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel30
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine27
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review26
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies26
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China24
Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis24
Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden24
Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures23
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States23
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups23
Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review23
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective23
0.053187131881714